Crystal Pharmatech

Crystal Pharmatech – From Solid Form to Clinical Formulation, Right the First Time Founded in 2010, Crystal Pharmatech is a global leader in solid form and formulation science, dedicated to transforming molecules into medicines right the first time. With over clients and more than compounds supported, we bring unmatched expertise across solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. Operating from four R&D centers in New Jersey, California, Toronto, and Suzhou, our 300-member team delivers integrated solutions powered by science, precision, and collaboration. Our cGMP facilities meet FDA, EMA, and NMPA standards, ensuring global quality and compliance. As a pioneer in enabling formulation technologies — including amorphous solid dispersion — we streamline development from developability assessment to clinical trial manufacturing (CTM) and commercial scale-up. Our signature Mol2Med™ Program accelerates small-molecule candidates from lead optimization or preclinical candidate (PCC) stage to Phase I and beyond through a proven three-step, First-Time-Right approach: Step 1: Developability Assessment – Guiding API form selection and formulation design. Step 2: Solid Form Screening & Preformulation – Ensuring stability and performance. Step 3: Formulation Development & CTM Manufacturing – Including packaging, labeling, and clinical-site delivery. This integrated pathway ensures a robust API form, scalable process, and a First-Time-Right formulation that sets the foundation for seamless advancement into future clinical phases.